

# Evidence dossier - Torray Funds

GetCoattail manager profile: <https://getcoattail.com/manager/torray-funds> | CIK 0000098758 | Rank #126 of 149 tracked managers by reported 13F value.

Background: Founded: 1972 | HQ: Bethesda, Maryland, U.S. | Style: U.S. equity, prudent growth with value and growth strategies | Key person: Robert E. Torray

Background

source:

<https://www.businesswire.com/news/home/20230215005257/en/Long-tenured-Fund-Reboots-with-Reorganization-Hires-Distribution-Specialist>

## 1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-07-30 Reported total value: \$741M Positions: 91 Top-10 concentration: 34.9% of reported value.

| Ticker | Company                  | Weight | Reported value |
|--------|--------------------------|--------|----------------|
| AVGO   | Broadcom                 | 5.17%  | \$38M          |
| RPRX   | Royalty Pharma Plc       | 4.55%  | \$34M          |
| CEG    | Constellation Energy     | 3.61%  | \$27M          |
| CNA    | Cna Financial            | 3.42%  | \$25M          |
|        | Alphabet Convertible Pfd | 3.22%  | \$24M          |
| KKR    | Kkr Series D Conv 6.25   | 3.08%  | \$23M          |
| CVX    | Chevron Corp             | 3.03%  | \$22M          |
| BX     | Blackstone               | 3.00%  | \$22M          |
| AMGN   | Amgen                    | 2.92%  | \$22M          |
| CMCSA  | Comcast Class A          | 2.86%  | \$21M          |

## 2. Hypothetical 13F-clone results

Window: 2016-11-09 to 2026-10-02 (40 filings). Cumulative: +232.7% CAGR: +12.92% SPY same window: cumulative +316.5%, CAGR +15.51%. Trailing CAGR - 10Y: n/a, 5Y: +11.36%, 3Y: +17.28%, 1Y: +11.85%. Max drawdown (month-end, approximate): -23.4%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

## 3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

| Quarter | Accession no.        | Filed      | CUSIPs |
|---------|----------------------|------------|--------|
| 2016Q3  | 0000950123-16-021522 | 2016-11-09 | 85     |
| 2016Q4  | 0000950123-17-002576 | 2017-02-15 | 110    |
| 2017Q1  | 0000950123-17-004798 | 2017-05-12 | 106    |
| 2017Q2  | 0000950123-17-006700 | 2017-08-04 | 105    |
| 2017Q3  | 0000950123-17-009980 | 2017-11-09 | 105    |

|        |                      |            |     |
|--------|----------------------|------------|-----|
| 2017Q4 | 0000950123-18-001636 | 2018-02-13 | 108 |
| 2018Q1 | 0000950123-18-005274 | 2018-05-14 | 105 |
| 2018Q2 | 0000950123-18-008551 | 2018-08-14 | 103 |
| 2018Q3 | 0000950123-18-010457 | 2018-11-02 | 102 |
| 2018Q4 | 0000950123-19-000716 | 2019-02-06 | 102 |
| 2019Q1 | 0000950123-19-003980 | 2019-05-07 | 104 |
| 2019Q2 | 0000950123-19-007282 | 2019-08-08 | 106 |
| 2019Q3 | 0000950123-19-010175 | 2019-11-06 | 102 |
| 2019Q4 | 0000950123-20-001456 | 2020-02-11 | 102 |
| 2020Q1 | 0000950123-20-003688 | 2020-04-30 | 97  |
| 2020Q2 | 0000950123-20-007503 | 2020-08-03 | 99  |
| 2020Q3 | 0000950123-20-010673 | 2020-11-02 | 99  |
| 2020Q4 | 0000950123-21-000923 | 2021-02-03 | 100 |
| 2021Q1 | 0000950123-21-005228 | 2021-05-03 | 103 |
| 2021Q2 | 0000950123-21-009569 | 2021-08-03 | 102 |
| 2021Q3 | 0000950123-21-013815 | 2021-11-02 | 98  |
| 2021Q4 | 0000950123-22-001002 | 2022-02-04 | 107 |
| 2022Q1 | 0000950123-22-004467 | 2022-05-03 | 100 |
| 2022Q2 | 0000950123-22-007687 | 2022-08-03 | 99  |
| 2022Q3 | 0000950123-22-010814 | 2022-11-04 | 100 |
| 2022Q4 | 0000950123-23-001003 | 2023-02-08 | 104 |
| 2023Q1 | 0000950123-23-003582 | 2023-05-02 | 100 |
| 2023Q2 | 0000950123-23-006177 | 2023-07-20 | 96  |
| 2023Q3 | 0000950123-23-009574 | 2023-11-08 | 94  |
| 2023Q4 | 0000950123-24-001107 | 2024-02-08 | 94  |
| 2024Q1 | 0000950123-24-004341 | 2024-05-10 | 92  |
| 2024Q2 | 0000950123-24-007212 | 2024-08-06 | 93  |
| 2024Q3 | 0000950123-24-010363 | 2024-11-05 | 102 |
| 2024Q4 | 0000950123-25-001012 | 2025-02-06 | 101 |
| 2025Q1 | 0000950123-25-004292 | 2025-05-08 | 101 |
| 2025Q2 | 0000950123-25-006998 | 2025-08-05 | 99  |
| 2025Q3 | 0001193125-25-246260 | 2025-10-22 | 99  |
| 2025Q4 | 0001193125-26-027064 | 2026-01-28 | 95  |
| 2026Q1 | 0001193125-26-200972 | 2026-05-01 | 88  |
| 2026Q2 | 0001193125-26-326274 | 2026-07-30 | 91  |

## 4. Coverage and adjustments

Price coverage at the latest filing: 82.4% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

## 5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.